ProductLife Group contributes eight scientific posters exploring health economics, treatment outcomes, HTA, pricing and patient access.
November 2026 | Vienna, Austria
Demonstrating the clinical benefits of a treatment is essential. But determining its value also requires understanding its economic impact, comparative outcomes, long-term benefits and accessibility within healthcare systems.
These questions are central to ISPOR Europe 2026, where ProductLife Group (PLG) contributes to the scientific programme with eight research posters.
Spanning multiple therapeutic areas and methodological approaches, these contributions examine some of the most relevant challenges in health economics and outcomes research (HEOR): how to assess treatment value, compare therapeutic alternatives, understand the burden of disease and evaluate the relationship between regulatory approval and patient access.
Together, they reflect the importance of connecting clinical evidence, economic evaluation and healthcare decision-making.
PLG contributes seven scientific posters addressing economic evaluation, comparative effectiveness, disease burden and value assessment across several therapeutic areas.
The research reflects PLG's expertise in health economics and modelling, generating evidence that supports informed healthcare decisions.
The scientific contributions are presented by PLG colleagues, including Belén Citoler Berdala, Service Line Lead – Health Economics & Modeling, and Neus Vidal Vilar, Service Line Lead – Market Access & Pricing & Strategy.
EE61 | Value of Cladribine Tablets Treatment Persistence in Relapsing-Remitting Multiple Sclerosis: Quantifying the Economic Impact From the Spanish Healthcare System Perspective
An analysis examining the economic implications of treatment persistence in relapsing-remitting multiple sclerosis within the Spanish healthcare system.
EE274 | Economic Evaluation of Biologic Treatment Sequences in Systemic Lupus Erythematosus in Spain
An economic evaluation focusing on biologic treatment sequencing strategies in systemic lupus erythematosus.
EE732 | Cost-Per-Responder Analysis of Ritlecitinib Versus Baricitinib in Severe Alopecia Areata: A Spanish Healthcare Perspective
A comparative analysis examining treatment costs in relation to clinical response for two therapeutic options in severe alopecia areata.
EE727 | Cost-Effectiveness of Tezepelumab versus Dupilumab and Mepolizumab in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Spain
A cost-effectiveness analysis comparing therapeutic alternatives for patients with chronic rhinosinusitis with nasal polyps.
CO85 | Mid- and Long-Term Number Needed to Treat for Tildrakizumab 200 mg in Moderate-to-Severe Plaque Psoriasis Patients with Body Weight ≥90 kg
Research exploring treatment outcomes using the number needed to treat as a measure of therapeutic effectiveness over different time horizons.
CO55 | Burden of Clostridioides difficile Infection (CDI) in Patients at High Risk of Recurrence in Spain
An assessment of the burden associated with Clostridioides difficile infection in patients at increased risk of recurrence.
HTA199 | Value Contribution of Donidalorsen for the Long-Term Prophylaxis of Hereditary Angioedema in Spain: a Multi-Criteria Decision Analysis (MCDA)
This research applies a multi-criteria decision analysis approach to examine the value contribution of donidalorsen for long-term prophylaxis of hereditary angioedema.
PLG also contributes a scientific poster examining the relationship between regulatory approval and patient access timelines across the United States and Europe.
The research is authored by Giulia Fagnocchi, Stefania Brancone, Letizia Rossi, Virginia Niglio, Mariangela Prada and Claudia Bertozzi, bringing together expertise in health economics, market access, value evidence and medical strategy.
HPR255 | Regulatory Approval and Patient Access Timelines in the US and Europe: A Baseline Analysis to Inform Potential Effects of Most-Favoured-Nation Pricing Policies
The study examines regulatory approval and patient access timelines in the US and Europe, establishing a baseline to inform the assessment of potential effects associated with Most-Favoured-Nation pricing policies.
The research addresses a fundamental challenge for the pharmaceutical industry: understanding how regulatory and pricing frameworks may influence the time between product approval and patient access.
Taken together, these eight scientific contributions demonstrate the breadth of evidence required to inform healthcare decisions.
Economic models help assess the implications of treatment choices. Comparative outcomes research provides perspectives on therapeutic value. HTA methodologies support structured assessments, while pricing and access analyses contribute to understanding the policy environment in which medicines reach patients.
The challenge is not simply to generate more evidence, but to generate the right evidence for the decisions that matter.
This requires scientific and methodological expertise combined with an understanding of regulatory requirements, payer expectations and the characteristics of individual healthcare systems.
Through its Market & Patient Access capabilities, PLG brings together expertise in health economics and outcomes research (HEOR), HTA strategy and support, pricing and reimbursement, patient-centred research, real-world data and real-world evidence (RWD/RWE), market research and intelligence, and patient programmes.
With global capabilities and local expertise, PLG supports life sciences organisations in building evidence strategies, addressing reimbursement uncertainty and preparing for market access across different healthcare systems.
PLG's participation in ISPOR Europe 2026 reflects the Group's commitment to scientific research and the development of evidence that supports healthcare decision-making.
The eight posters demonstrate how different analytical approaches contribute to a more comprehensive understanding of treatment value, healthcare resource allocation and patient access.
As the requirements for demonstrating healthcare value continue to evolve, integrating economic, clinical and access-related evidence remains essential to supporting informed decisions throughout the product lifecycle.
Explore PLG's solutions and expertise and contact PLG to discuss how our Market & Patient Access capabilities can support your evidence generation, HTA, pricing and reimbursement strategies.